MANNKIND CORP Proceeds from Long-Term Debt Issued
MANNKIND CORP (MNKD) reported Proceeds from Long-Term Debt Issued of $4.87 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-02-23
- MANNKIND CORP proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $0.00.
- MANNKIND CORP proceeds from issuance of long-term debt for the quarter ending 2020-09-30 was $0.00.
- MANNKIND CORP proceeds from issuance of long-term debt for the quarter ending 2014-12-31 was $0.00.
- MANNKIND CORP proceeds from issuance of long-term debt for the quarter ending 2014-09-30 was $0.00.
- MANNKIND CORP proceeds from issuance of long-term debt for fiscal 2020 was $4.87M.
- MANNKIND CORP proceeds from issuance of long-term debt for fiscal 2014 was $20.00M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month | Proceeds from Issuance of Long-term Debt 280 month | Proceeds from Issuance of Long-term Debt 283 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $4.87M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.87M 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | $4.87M 10-Q · filed 2021-08-11 | |||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $20.00M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $20.00M 10-Q · filed 2015-11-09 | $20.00M 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $20.00M 10-Q · filed 2015-08-10 | $20.00M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |